Detalhe da pesquisa
1.
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.
Mol Ther
; 32(2): 503-526, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38155568
2.
Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion.
J Infect Dis
; 225(7): 1118-1123, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34940844
3.
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 380(18): 1726-1737, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31042825
4.
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
Crit Care Med
; 50(1): 81-92, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34259446
5.
Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products.
J Transl Med
; 20(1): 514, 2022 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36348415
6.
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Mol Ther
; 29(2): 702-717, 2021 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33129371
7.
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.
Blood
; 132(8): 804-814, 2018 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29895668
8.
FDA approval of the first cellular therapy for a solid (non-hematologic) cancer.
Mol Ther
; 32(4): 857-858, 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38503296
9.
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.
Mol Ther
; 27(7): 1275-1285, 2019 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178392
10.
Chimeric antigen receptor T-cell therapies for multiple myeloma.
Blood
; 130(24): 2594-2602, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28928126
11.
Versatile strategy for controlling the specificity and activity of engineered T cells.
Proc Natl Acad Sci U S A
; 113(4): E450-8, 2016 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26759368
12.
Toxicities of chimeric antigen receptor T cells: recognition and management.
Blood
; 127(26): 3321-30, 2016 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27207799
13.
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.
Blood
; 127(10): 1361-70, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26660684
14.
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Blood
; 128(13): 1688-700, 2016 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27412889
15.
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
Blood
; 128(4): 519-28, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27226436
16.
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Mol Ther
; 25(11): 2452-2465, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807568
17.
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Mol Ther
; 25(10): 2245-2253, 2017 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28803861
18.
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. Reply.
N Engl J Med
; 381(3): e6, 2019 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31314982
19.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lancet
; 385(9967): 517-528, 2015 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25319501
20.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood
; 122(25): 4129-39, 2013 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24055823